MINUTES OF MEETING: Q3 PORTFOLIO STRATEGY REVIEW

Date: August 15, 2025

Location: AstraGen HQ, Conference Room A (and via Teams)

Attendees: * Dr. Sarah Chen (VP, R&D)

- Mark Reynolds (Global Supply Chain Lead)
- Priya Sharma (Commercial Head - Dermatology)
- David O'Connor (Head of Business Development)

Agenda Items

1. Review of Q2 Performance

- Overall revenue is on target.
- **TelmiGuard (Telmisartan)** continues to perform well; supply chain is stable.
- **MinoClear (Minocycline)** is underperforming. Revenue is down 4.5%.

2. The "Minocycline Problem"

Mark Reynolds (Supply Chain): Raised a red flag regarding the Baddi facility. We have over 4,000 kg of Minocycline API sitting in warehouses. If we don't move this volume, we will be forced to write off $2.5M in inventory by next year.

Priya Sharma (Commercial): The acne market is saturated. We cannot sell more volume there. We are losing share to isotretinoin.

Dr. Sarah Chen (R&D): We need to look outside dermatology. Minocycline is a unique molecule—it's highly lipophilic and crosses the Blood-Brain Barrier. There is academic literature suggesting it works for neuro-inflammation.

3. Action Items & Decisions

- **Decision:** "Project Second Life" is approved. We will investigate repurposing Minocycline for a Central Nervous System (CNS) indication.
- **Action (R&D Team):** Conduct a "Deep Dive" literature review.
    - *Constraint:* Manual review takes too long (estimated 3 months).
    - *Directive:* Use the new **Agentic AI Pilot Tool** to scan PubMed, ClinicalTrials.gov, and Patent databases.
    - *Target:* We need a "Go/No-Go" decision on a CNS indication (Depression? Alzheimer's? MS?) within 1 week.

4. AOB (Any Other Business)

- Update on Telmisartan/Amlodipine launch timeline (on track).
- FDA audit of the Cork facility scheduled for next month.

Meeting Adjourned: 11:30 AM EST

Minutes Recorded By: J. Doe, Executive Assistant

CONFIDENTIAL: Internal Circulation Only.